Building, partnering, or buying
Building alone puts recertification on the critical path and ships nothing for two years; an acquisition buys a year, not the target.
Building alone is the base case above. Its defining feature is that recertification sits on the critical path and nothing ships for two years.
Buying changes one thing, and it is the right thing: it removes the certificate and the customer qualification from the critical path. A target that already holds ISO 13485, an audited quality system and qualified customer relationships would pull Line A forward by about a year and Line B by rather more, which is worth roughly $48M of 2029 revenue in the high scenario.
What it does not do is buy the target. At a 1.7 times revenue multiple typical of private medical component businesses at this scale, the $35M reference buys about $21M of revenue. To buy $350M of revenue would cost around $595M, which is 17 times the stated reference.
On the named candidates:
Precision Neuroscience raised $102M in a Series C in December 2024, reported as $104M by a second source, and holds 510(k) clearance for a 1,024-electrode cortical array. It is a BCI company, in the segment with no near-term revenue, and it is priced as a venture asset rather than as a component business. Three times the reference scale for a pre-commercial position.
InBrain Neuroelectronics is a graphene-based BCI platform, also pre-commercial, and the same objection applies with a technology MERIDIAN does not hold.
GBrain is the most interesting of the three and the only one operating in the component layer this analysis says MERIDIAN should occupy. It is based in Songdo, Incheon, and describes itself as the first Korean maker of invasive electrodes to produce flexible thin-film electrode arrays for high-resolution cortical recording and stimulation. It showed a cortical monitoring and stimulation implant system at CES 2025, where it took one of the innovation awards given to Incheon startups, and exhibited at MEDICA 2025. It is led by a professor of nano-bioengineering at Incheon University alongside a former Celltrion executive, and its disclosed funding is accelerator-stage.
Assessed against the four partner criteria: it fails the revenue test by a wide margin and there is no public evidence of a live ISO 13485 certificate or of qualified supplier status with a named customer. Its manufacturing is research-scale.
That makes it an acquisition that would buy technology and people rather than a certificate, a customer list or capacity, which are the three things MERIDIAN actually lacks. It is a reasonable target for the interventional line and it does nothing for the calendar, which is the binding constraint. It is also the one candidate close enough to home that a development agreement would cost almost nothing to try first.
How the startups in these ecosystems are positioned
The brief asks where startups sit across materials, components, modules, systems and services. They cluster at the two ends and leave the middle empty, which is the part that matters here.
- Who is there
- INBRAIN Neuroelectronics, working on graphene-based electrodes
- What it means for MERIDIAN
- Venture-funded, pre-commercial, and a materials position MERIDIAN does not hold
- Who is there
- NeuroOne, which prints thin-film electrodes using semiconductor-like processes and has commercialized them for epilepsy monitoring. CorTec, WISE, Neurosoft Bioelectronics
- What it means for MERIDIAN
- This is MERIDIAN's layer, and it is populated by small specialists rather than by scale manufacturers. NeuroOne is the closest working analog to Line C
- Who is there
- Almost nobody
- What it means for MERIDIAN
- The gap. No startup is building a business selling assembled single-use electronic modules to device and pharmaceutical companies at volume, because that requires manufacturing scale a startup does not have
- Who is there
- Precision Neuroscience, Paradromics (about $105M of venture capital plus $18M of federal grants), Neuralink, Synchron
- What it means for MERIDIAN
- Where the capital is. These are customers or competitors for talent, not acquisition targets at the reference scale
- Who is there
- The contract manufacturers: Cirtec, Integer, MicroConnex
- What it means for MERIDIAN
- Established, not startups
Two things follow. The module layer being empty is consistent with the recommendation: MERIDIAN's scale is the reason it can occupy a position a startup cannot, and the absence of startups there is evidence of a real barrier rather than of an absent market.
And the startups worth acquiring for the component layer are small enough to be affordable and too small to move the target. NeuroOne is the type specimen: a real thin-film electrode business with a cleared product, at a scale that adds capability rather than revenue.
Echo cannot be assessed at all. The brief identifies it only as a current exploratory partner under NDA. What it does, at what stage, at what price and under what ownership are not in the inputs, and no amount of research resolves an unidentified company. What can be said is what a partner would have to have, and that is answerable.
What a partner must possess to change the outcome, in priority order:
- A live ISO 13485 certificate with an unbroken audit history. This is the only attribute that shortens the calendar, and the calendar is the binding constraint.
- Qualified supplier status with at least one named customer already shipping. A relationship is not a qualification.
- Manufacturing that is volume-capable or credibly convertible. A company making hundreds of units a year has no process MERIDIAN needs.
- Revenue over $15M. Below that the acquisition buys a capability, not a business, and capability MERIDIAN largely has.
A partner strong on the first two and weak on the third is worth more than the reverse, because MERIDIAN's own asset is volume manufacturing and its gap is regulatory standing.
The honest ranking: buy beats build on time-to-revenue and neither reaches the target. Partnering without equity is the cheapest way to test Line B, because a development agreement with a pharmaceutical customer requires no acquisition and produces the evidence the scale decision needs.